Author/Authors :
Tang Hong نويسنده , Zhang Dong-Mei نويسنده , Wang Juan نويسنده , Bai Lang نويسنده Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, Republic of China , Chen En Qiang نويسنده Infectious Diseases Center, West China Hospital, Sichuan
University, Chengdu, China , Wang Meng-Lan نويسنده Center of Infectious Diseases, West China Hospital of
Sichuan University, Chengdu 610041, PR China , Lv Xiao-Fang نويسنده Center of Infectious Diseases, West China Hospital of
Sichuan University, Chengdu 610041, PR China , Tao Ya-Chao نويسنده Center of Infectious Diseases, West China Hospital of
Sichuan University, Chengdu 610041, PR China
Abstract :
Objectives This study aimed to assess the knowledge of junior
doctors on the 2015 chronic hepatitis B (CHB) guideline recommended by
Chinese society of infectious diseases and Chinese society of
hepatology, Chinese medical association. Methods Junior doctors, who
were already engaged in the field of CHB, were invited to complete a
questionnaire-based survey between May and June 2016. The questionnaire
consisted of 28 items focusing on knowledge in the following three
sections: mother-to-child transmission (MTCT) prevention,
response-guided therapy (RGT) strategies, and special patients’
antiviral therapy. Results Responses were received from 562 out of 600
participants. Among those 562 junior doctors, about 10%~30% were not
familiar with the use of hepatitis B vaccine and hepatitis B
immunoglobulin (HBIG), and 18.8% did not know that newborn with
HBsAg-positive mother could be breastfed after giving HBIG and vaccine.
About 20.6% of junior doctors did not know the possible withdrawal
indications recommended by the guideline. For HBeAg-positive patients
receiving low genetic barrier drugs, about 30% of junior doctors did not
know that the antiviral strategies should be adjusted according to HBV
DNA levels at treatment week 24. For CHB patients receiving
chemotherapy, about 25% of participants did not know antiviral therapy
should be started at least 1 week earlier, and about 20% did not know
that adefovir dipivoxil or tenofovir disoproxil fumarate should be
avoided in patients with kidney diseases or high-risk of developing
kidney diseases. Conclusions The knowledge on CHB guideline was rather
unsatisfactory in junior doctors. Our finding highlights the urgent need
for strengthening junior doctors to gain a greater understanding of CHB
guideline.